Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 7/20 | 0.41 |
| ▸ | MAP2K7 | O14733 | 2/20 | 0.41 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.37 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21046877 | 0.73 | MAP2K4 (0.58) | KMT2AMEN1BRAFMAP2K7MAP2K4 | |
| SCHEMBL18424329 | 0.68 | KMT2A (0.69) | KMT2AMEN1MAP2K7MAP2K4GAA | |
| SCHEMBL12474917 | 0.66 | KMT2A (0.65) | KMT2ACYP17A1MEN1GAASLC40A1 | |
| SCHEMBL4879656 | 0.66 | L3MBTL1 (0.47) | KMT2AMEN1BRAFGAA | |
| SCHEMBL4875782 | 0.65 | CA12 (0.48) | KMT2ABRAFPIK3CA | |
| SCHEMBL19872439 | 0.64 | MAP2K7 (0.42) | KMT2ACYP17A1MEN1BRAFMAP2K7 | |
| SCHEMBL21046972 | 0.64 | MAP2K4 (0.65) | BRAFMAP2K7MAP2K4 | |
| SCHEMBL23565665 | 0.64 | KMT2A (0.71) | KMT2AMEN1MAP2K7MAP2K4GAA | |
| SCHEMBL4879480 | 0.64 | HTR6 (0.56) | KMT2AMEN1GAA | |
| SCHEMBL9954104 | 0.63 | GAA (0.81) | KMT2ACYP17A1MEN1GAASLC40A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018030466-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 | 2018-02-15 | — | — | WO | disclosed |